Comparing SG&A Expenses: GSK plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights

A Tale of Two Companies: SG&A Expenses Over Time

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of GSK plc and Arrowhead Pharmaceuticals, Inc. from 2014 to 2023. GSK, a stalwart in the industry, consistently reported SG&A expenses in the range of $8.2 billion to $11.5 billion, reflecting its expansive global operations. In contrast, Arrowhead Pharmaceuticals, a smaller player, showed a dynamic growth trajectory, with expenses increasing from approximately $24 million in 2014 to $124 million in 2022, marking a fivefold increase. Notably, 2023 data for GSK is missing, highlighting potential reporting delays or strategic shifts. This comparison underscores the diverse financial strategies employed by large and small pharmaceutical companies, offering insights into their operational priorities and market positioning.